GO
| HSI1 | 23,093.37 | +158.69 | 249.78B |
| HSCEI1 | 7,756.25 | +67.06 | 87.14B |
| Back Zoom + Zoom - Block Traded | |
|
2026-10-22 17:33:02 UBS published a research report expecting China's CRO sector to deliver resilient third-quarter results, supported by strong demand and healthy order growth. Biopharmaceutical financing remained solid, while the drag from legacy low-priced orders may further ease. The broker is focusing on backlog momentum. The Hang Seng Innovative Drug Index rebounded 18% in the third quarter, which may support fair value investments, although the RMB appreciated 6.2% YoY against the USD, making foreign exchange a potential negative factor. UBS said WUXI APPTEC (02359.HK) recorded strong TIDES revenue growth in the third quarter, with full-year TIDES revenue growth guidance at around 45%, compared with 44.3% growth in the first half, implying accelerated growth in the second half. Small molecule revenue is expected to maintain healthy momentum. WUXI APPTEC (02359.HK) raised the upper end of its revenue guidance for this year from RMB53 billion to RMB60.5 billion. UBS lifted its TP from HKD237.4 to HKD243.9, reiterated its Buy rating, and maintained the stock as its sector top pick. The broker is also positive on WUXI XDC (02268.HK), expecting its revenue CAGR to reach 30% to 35% from 2025 to 2030.(gc/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |